NORTH CHICAGO, Ill., Aug. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

- New insights uncover how patients and caregivers cope emotionally during phases of Chronic Lymphocytic Leukemia (CLL)
- The findings also show majority of HCPs view treating CLL patients as different from treating other cancers
- The emotional complexities of this slow-growing cancer point to patient and caregiver need for greater support from HCPs at time of diagnosis

 Epcoritamab shows clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients
Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR; patients previously treated with CAR T achieved a 54 percent ORR and 34 percent CR
–  Safety profile is consistent with previous findings observed
Results were reported as part of a late-breaking oral presentation selected for the Presidential Symposium at EHA

NORTH CHICAGO, Ill., June 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These preliminary findings show spleen volume and symptomatic improvement in this cohort. These data are consistent with previously observed data from relapsed/refractory patients in Cohort 1a1 and will be shared in an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress (Abstract #S197).2

NORTH CHICAGO, Ill., June 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced five-year follow-up results from the Phase 3 CLL14 trial, finding that over 60 percent of patients with previously untreated chronic lymphocytic leukemia (CLL) who had received one-year fixed-duration combination treatment of VENCLYXTO®/VENCLEXTA® (venetoclax) plus obinutuzumab (GAZYVA®) continued to show longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease (MRD) after four years off treatment.1 The findings were presented at the 2022 European Hematology Association (EHA) Annual Congress (Abstract #S148).

NORTH CHICAGO, Ill., May 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and the European Hematology Association (EHA) Congress (June 9-17).

-          Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities
-          Data from the clinical trial to be presented at a future medical meeting
-          Large B-cell lymphoma (LBCL) is a common form of non-Hodgkin's lymphoma (NHL) and currently has limited treatment options

NORTH CHICAGO, Ill., April 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. The results were presented at the American Association for Cancer Research annual meeting (AACR 2022, abstract #LB108). Navitoclax is an investigational, first-in-class, oral BCL-XL/BCL-2 inhibitor that is designed to activate programmed cell death (apoptosis) in cancer cells. Navitoclax and its safety and efficacy are under evaluation as part of ongoing Phase 2 and registrational Phase 3 studies.

See how scientists have nearly doubled some survival rates in a generation, with even more scientific discoveries on the horizon.

NORTH CHICAGO, Ill., Jan. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.